AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
A Study to Investigate the Relative Bioavailability of AZD8630 Following a Device and Formulation Transition in Healthy Participants.
Phase 1
Completed
- Conditions
- Healthy Participants
- Interventions
- Drug: AZD8630 (test formulation) via test inhalerDrug: AZD8630 (reference formulation) via Monodose inhalerDevice: Test inhalerDevice: Monodose inhaler
- First Posted Date
- 2024-08-01
- Last Posted Date
- 2024-10-17
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 32
- Registration Number
- NCT06531811
- Locations
- 🇺🇸
Research Site, Baltimore, Maryland, United States
Post-marketing Phase 4 Safety & Tolerability Study of Breztri aerosphereTM in Indian Patients With Chronic Obstructive Pulmonary Disease
- First Posted Date
- 2024-08-01
- Last Posted Date
- 2025-05-11
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 150
- Registration Number
- NCT06531798
A Dose Range-Finding Study to Assess the Efficacy and Safety of Multiple Dose Levels of AZD8630 in Adults With Uncontrolled Asthma at Risk of Exacerbations
- First Posted Date
- 2024-07-31
- Last Posted Date
- 2025-05-20
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 516
- Registration Number
- NCT06529419
- Locations
- 🇬🇧
Research Site, Portsmouth, United Kingdom
AZD0486 as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL
Phase 2
Recruiting
- Conditions
- B-cell Non-Hodgkin LymphomaFollicular Lymphoma (FL)Diffuse Large B-Cell Lymphoma (DLBCL)
- Interventions
- First Posted Date
- 2024-07-30
- Last Posted Date
- 2025-04-27
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 240
- Registration Number
- NCT06526793
- Locations
- 🇬🇧
Research Site, Plymouth, United Kingdom
A Study to Assess the PK, PD, Safety and Tolerability of Eplontersen in Healthy Chinese Volunteers
Phase 1
Completed
- Conditions
- Transthyretin-mediated Amyloidosis
- Interventions
- First Posted Date
- 2024-07-30
- Last Posted Date
- 2024-11-21
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 12
- Registration Number
- NCT06527755
- Locations
- 🇨🇳
Research Site, Beijing, China
A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Inhaled AZD4604 in Healthy Japanese and Chinese Participants.
- First Posted Date
- 2024-07-25
- Last Posted Date
- 2025-01-10
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 56
- Registration Number
- NCT06519968
- Locations
- 🇬🇧
Research Site, Harrow, United Kingdom
Clinical& Demographic Profiles of patIents With unControllEd Asthma in Russia: Multi-center oBsErvational ReGistry Study
Recruiting
- Conditions
- Uncontrolled Asthma
- First Posted Date
- 2024-07-25
- Last Posted Date
- 2025-05-23
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 10000
- Registration Number
- NCT06521229
- Locations
- 🇷🇺
Research Site, Yuzhno-Sakhalinsk, Russian Federation
Exacerbations Among Patients Receiving Breztri (EROS Study)
- First Posted Date
- 2024-07-23
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 2409
- Registration Number
- NCT06514144
- Locations
- 🇺🇸
AstraZeneca, Wilmington, Delaware, United States
Phase I PK Study of Budesonide/Albuterol Delivered From PT027 in Healthy Chinese Participants.
Phase 1
Not yet recruiting
- Conditions
- Healthy Volunteer
- Interventions
- Combination Product: budesonide/albuterol sulfate metered dose inhaleor (BDA MDI)
- First Posted Date
- 2024-07-23
- Last Posted Date
- 2024-07-23
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 14
- Registration Number
- NCT06514157
- Locations
- 🇨🇳
Research Site, Shanghai, China
A Trial to Investigate Benralizumab in Children With Eosinophilic Diseases
Phase 3
Recruiting
- Conditions
- Eosinophilic Granulomatosis With Polyangiitis (EGPA)
- Interventions
- First Posted Date
- 2024-07-22
- Last Posted Date
- 2025-05-09
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 14
- Registration Number
- NCT06512883
- Locations
- 🇹🇷
Research Site, Istanbul, Turkey
© Copyright 2025. All Rights Reserved by MedPath